Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).-MedSci.cn

Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).

Deming, DA; Emmerich, P; Turk, AA; Lubner, SJ; Uboha, NV; LoConte, NK; Mulkerin, D; Kim, DH; Matkowskyj, KA; Weber, SM; Abbott, D; Eickhoff, JC; Bassetti, MF

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务